In this study we investigated whether treatment of pre-clinical models of CRLF2 B-ALL, both cell lines and PDXs, with increasing concentrations of TSLP has major effects on leukemia cell survival in vitro and leukemia burden in vivo. The gene discussed is CRLF2; the disease is acute lymphoblastic leukemia.